Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

Year Ended December 31, 

​

    

2023

    

2022

Revenue

​

​

​

​

​

​

Qbrexza

​

$

25,410

​

$

26,715

Accutane

​

​

20,168

​

​

18,373

Amzeeq

​

​

6,201

​

​

7,242

Zilxi

​

​

1,962

​

​

2,273

Targadox

​

​

3,204

​

​

7,972

Exelderm

​

​

2,395

​

​

3,463

Ximino

​

​

287

​

​

4,957

Luxamend

​

​

35

​

​

—

Collaboration revenue

​

​

5,229

​

​

1,882

Revenue – related party

​

 

103

​

 

192

Other revenue

​

​

19,519

​

 

2,674

Total net revenue

​

$

84,513

​

$

75,743